focus -WSS

focus

author：knowledge 2025-10-01 11:36:34 - browse：785

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： SEC charges former device maker CEO with $41 million fraud

Wikipedia

WSS

Grail spinoff by Illumina should end disastrous merger attempt

Cancer cells are shown to suck energy source from immune cells

What the Wegovy shortage looks like for doctors — and for patients

Massive project maps cells in human brain in unprecedented detail

What STAT readers think about the FDA and patient advocacy

How clinical AI models' predictive power can degrade over time

leisure time

focus

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Walensky prepares to leave CDC — and Congress — behind

Hospitals owned by private equity see complications spike 25%

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

European regulators consider appeal over Amylyx ALS drug

Continuity nursing helped my family in our darkest PICU moments

CRISPR gene editing developments we’re watching in 2024

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Readout: Today's biotech news includes Sana and Amylyx

leisure time

SEC charges former device maker CEO with $41 million fraud

Editas, Vertex strike deal on CRISPR

Christmas in the PICU brings some surprising joy

Better Therapeutics data on benefit with GLP

David Ricks of Eli Lilly: best biopharma CEO of 2023

Drinking less cuts risk of oral cavity, esophageal cancer: Report

hotspot

Wikipedia

Wikipedia

focus